CLE-400
a Potent Analgesic Topical Gel in Acute and Chronic Pain Pig Models

Dr. Elanite Caspi

IASP 2021 Virtual World Congress on Pain
9-11 June, 16-18 June 2021
ID#: 1036172
Disclaimer

This presentation has been prepared by Clexio Biosciences Ltd. (the “Company”) and is general background information about the Company’s activities at the date of this presentation. The information in this presentation is provided in summary form only and does not purport to be complete. This presentation does not contain all the information that is or may be material to investors/collaborators or potential investors/collaborators and should not be considered as advice or a recommendation to investors/collaborators or potential investors/collaborators. By attending the presentation or by reading the presentation slides you agree to be bound as follows: This presentation has been made to you solely for information purposes. This presentation may be amended and supplemented as the Company sees fit, may not be relied upon for the purpose of entering into any transaction and shall not be regarded as a recommendation in relation to any such transaction whatsoever. This presentation and its contents are proprietary to the Company, and no part of it or its subject matter may be reproduced, redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding the relevant person’s professional advisers) or published in whole or in part for any purpose without the prior written consent of the Company. If this presentation has been received in error it must be returned immediately to the Company. This presentation contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding business strategy, plans, targets and objectives of the management of the Company for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company’s ability to implement and achieve the budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this presentation speak only as of the date of this presentation, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Nothing in the foregoing is intended to or shall exclude any liability for, or remedy in respect of, fraudulent misrepresentation. The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the presentation and the information contained herein and no reliance should be placed on it. Information in this presentation (including market data and statistical information) has been obtained from various sources (including third party sources) and the Company does not guarantee the accuracy or completeness of such information. All projections, valuations and statistical analyses are provided for information purposes only. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, any they should not be relied upon as an accurate prediction of future performance. Any financial data in this presentation are solely for your information, as background to the Company and may not be relied upon for the purpose of entering into any transaction whatsoever. Furthermore, no representation is made as to the reasonableness of the assumptions made in this presentation or the accuracy or completeness of any modelling, scenario analysis or back-testing. The information in this presentation is not intended to predict actual results and no assurances are given with respect thereto. None of the Company, its advisers, connected persons or any other person accepts any liability whatsoever for any loss howsoever arising, directly or indirectly, from this presentation or its contents. All information, opinions and estimates contained herein are given as of the date hereof and are subject to change without notice.
Authors & Disclosures

• Elanite Caspi, PhD
• Johanna Schumann, PhD
• Orna Goren, PhD
• Elena Kagan

Clexio Biosciences, 17 Yegi’a Kapaim St., Petach Tikva, Israel
CLE-400 a Novel, Non-Opioid Topical Treatment for PDN

- CLE-400 is an aqueous gel of detomidine, a potent α2-adrenergic agonist activating additional potentially therapeutically relevant targets
- CLE-400 is a new investigational drug that has not been approved for commercial distribution

Targeting α2-adrenergic receptors peripherally

- Systemically administered α2-adrenergic agonists are used in pain management and anesthesia. Their use is limited to invasive RoA and may lead to systemic AEs
- Immunohistochemistry studies demonstrated that detomidine’s targets (α2-ARs, H4R and SST4R) are expressed in the skin
- Activation of these receptors could produce analgesic by inhibiting the excitability and neural signaling from the peripheral nociceptors (C-fibers) to the brain

The technology

- CLE-400 gel formulation was developed to deliver high dermal concentrations over extended period of time (depot effect in the skin) while maintaining limited systemic exposure
Detomidine: A Potent $\alpha_2$-Adrenergic Receptor Agonist activating additional potentially therapeutically relevant targets

Binding and functional assays with detomidine were conducted against a wide range of molecular targets in order to better understand its MOA

- Detomidine has been confirmed to be a potent activator of $\alpha_2$A adrenergic receptors *in vitro*
- It was also discovered that detomidine acts as an agonist of 2 secondary targets, histamine 4 (H4) and somatostatin 4 (sst4) receptors

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Activity</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha_2_A$ adrenergic</td>
<td>agonist</td>
<td>EC50 ~24 nM</td>
</tr>
<tr>
<td>Histamine (H4)</td>
<td>(partial) agonist</td>
<td>EC50 ~5µM</td>
</tr>
<tr>
<td>Somatostatin (sst4)</td>
<td>agonist</td>
<td>EC50 ~7µM</td>
</tr>
</tbody>
</table>

- Histopathological studies confirmed that detomidine's targets are expressed in the skin
- Detomidine's levels in the skin, as analyzed in pig skin, are in µM range, thus clinically relevant to all three targets
**CLE-400** exhibits a substantial analgesic effect in acute post-operative pig model

![Graph showing withdrawal response (g) following von Frey stimulation over 6 days.](image)

**CLE-400 was administered twice daily, for 6 consecutive days.** Mean (± SEM) group withdrawal response (g) following von Frey stimulation. *P<0.05; **P<0.01; ***p<0.001; ****p<0.0001 vs. placebo.

- ✓ Topical application of **CLE-400 0.33%** for 6 days resulted in a statistically significant increase in pain threshold as soon as Day 1 (2nd day of treatment); this effect gradually increased up to Day 5
- ✓ **CLE-400 gel** had no significant effect on locomotor activity, indicative of a lack of systemic toxicity (i.e. sedation)
CLE-400 exhibits a significant, dose dependent, analgesic effect in Peripheral Neuritis Trauma (chronic neuropathic pain) pig model

CLE-400 was administered twice daily, for 14 consecutive days. (A) Group withdrawal response (g) following von Frey stimulation. Mean (± SEM). #### p<0.0001 vs. baseline. *p<0.05; **p<0.01; ***p<0.001 ****p<0.0001 vs. Vehicle. (B) General behavior score. Mean (± SEM).*p<0.05; ***p<0.001 vs. Vehicle.

- CLE-400 exhibited a dose-dependent analgesic effect as early as 1 hour post application. Repeated dosing enhanced the analgesic effect up to Day 14
- CLE-400 resulted in a dose-dependent decrease in the behavior score starting several hours post treatment and throughout the entire study
- No sedation was observed
Conclusions

• Topical administration of CLE-400 demonstrated a robust pharmacological effect in an acute post-operative pig model and in a chronic neuropathic pain (PNT) pig model

• Detomidine has been confirmed to potently activate α2A adrenergic receptors in vitro, with additional modalities that might contribute to CLE-400 efficacy, presenting a possible multi-modal MOA

• Main and secondary targets of detomidine have been shown to be expressed in the skin, strengthening the proposition of local activity of CLE-400

• CLE-400 is generally well tolerated locally and systemically in efficacy and safety/toxicology studies
Thank you

You are welcome to contact us
Elanite.Caspi@Clexio.com | David.Dangoor@Clexio.com